[{"orgOrder":0,"company":"University of Siena","sponsor":"IBSA Institut Biochimique","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Amino Acid","year":"2014","type":"Inapplicable","leadProduct":"Selenium Methionine","moa":"Selenoprotein","graph1":"Immunology","graph2":"Phase II","graph3":"University of Siena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Siena \/ IBSA Institut Biochimique","highestDevelopmentStatusID":"8","companyTruncated":"University of Siena \/ IBSA Institut Biochimique"},{"orgOrder":0,"company":"University of Auckland, New Zealand","sponsor":"Cancer Trials New Zealand | Counties Manukau Health | Waikato Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NEW ZEALAND","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Selenium Methionine","moa":"Selenoprotein","graph1":"Gastroenterology","graph2":"Phase I","graph3":"University of Auckland, New Zealand","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Auckland, New Zealand \/ Cancer Trials New Zealand | Counties Manukau Health | Waikato Hospital","highestDevelopmentStatusID":"6","companyTruncated":"University of Auckland, New Zealand \/ Cancer Trials New Zealand | Counties Manukau Health | Waikato Hospital"},{"orgOrder":0,"company":"Mohammed Milhem","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Amino Acid","year":"2015","type":"Inapplicable","leadProduct":"Selenium Methionine","moa":"Selenoprotein","graph1":"Oncology","graph2":"Phase I","graph3":"Mohammed Milhem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mohammed Milhem \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Mohammed Milhem \/ Pfizer Inc"}]

Find Clinical Drug Pipeline Developments & Deals for (+-)-Selenomethionine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          University of Auckland, New Zealand

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          University of Auckland, New Zealand

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Selenomethionine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colorectal Adenoma.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          July 07, 2021

                          Lead Product(s) : Selenium Methionine

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Sponsor : Cancer Trials New Zealand | Counties Manukau Health | Waikato Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Mohammed Milhem

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Mohammed Milhem

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Selenomethionine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Renal Cell.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          August 28, 2015

                          Lead Product(s) : Selenium Methionine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Pfizer Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          University of Siena

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          University of Siena

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Selenomethionine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Thyroiditis, Autoimmune.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          November 27, 2014

                          Lead Product(s) : Selenium Methionine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : IBSA Institut Biochimique

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank